FDA Approves Enhertu® for HER2-Low MBC
On August 5, 2022, the FDA approved trastuzumab deruxtecan (Enhertu®) for the treatment of people with HER2-low MBC who have received chemotherapy. This new...
Read More PAST ARTICLES
2021
- Metastatic Breast Cancer News from 2021 ESMO
- Metastatic Breast Cancer News from ASCO 2021
- MBC News from 2021 AACR Meeting
- St. Gallen International Breast Cancer Conference 2021
- 2021 Miami Breast Cancer Conference
- FDA Approves MARGENZA
- What is Next-Generation Sequencing?
- Lines of Therapy: New Drugs May Change MBC Treatment
2020
SEARCH OUR SITE
for past articles or specific information.